期刊
EUROPEAN HEART JOURNAL
卷 40, 期 20, 页码 1643-+出版社
OXFORD UNIV PRESS
DOI: 10.1093/eurheartj/ehy234
关键词
Biomarker; Cardiovascular disease; Long non-coding RNAs; MicroRNAs; Non-coding RNAs; Personalized medicine; Precision medicine
资金
- Instituto de Salud Carlos III Grant [CD14/00109]
- Juan de la Cierva-Incorporacion grant from Ministerio de Economia y Competitividad [IJCI-2016-29393]
- Instituto de Salud Carlos III [CB16/11/00403]
- DFG [TH903/18-1]
- EU, project HOMAGE
- ERANET-CVD LIPCAR-HF
Current clinical guidelines emphasize the unmet need for technological innovations to guide physician decision-making and to transit from conventional care to personalized cardiovascular medicine. Biomarker-guided cardiovascular therapy represents an interesting approach to inform tailored treatment selection and monitor ongoing efficacy. However, results from previous publications cast some doubts about the clinical applicability of biomarkers to direct individualized treatment. In recent years, the non-coding human transcriptome has emerged as a new opportunity for the development of novel therapeutic strategies and biomarker discovery. Non-coding RNA (ncRNA) signatures may provide an accurate molecular fingerprint of patient phenotypes and capture levels of information that could complement traditional markers and established clinical variables. Importantly, ncRNAs have been identified in body fluids and their concentrations change with physiology and pathology, thus representing promising non-invasive biomarkers. Previous publications highlight the translational applicability of circulating ncRNAs for diagnosis and prognostic stratification within cardiology. Numerous independent studies have also evaluated the potential of the circulating non-coding transcriptome to predict and monitor response to cardiovascular treatment. However, this field has not been reviewed in detail. Here, we discuss the state-of-the-art research into circulating ncRNAs, specifically microRNAs and long non-coding RNAs, to support clinical decision-making in cardiovascular therapy. Furthermore, we summarize current methodological and conceptual limitations and propose future steps for their incorporation into personalized cardiology. Despite the lack of robust population-based studies and technical barriers, circulating ncRNAs emerge as a promising tool for biomarker-guided therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据